Highlights From NLA 2025: Early LDL-C Reduction and Emerging Therapies
July 9th 2025The 2025 National Lipid Association (NLA) Scientific Sessions highlighted a strategic shift toward early, aggressive cardiometabolic intervention, underscoring the vital role of pharmacists in implementing emerging therapies and optimizing cardiovascular risk reduction.
Read More
McKesson ideaShare 2025 Set to Empower Pharmacy Professionals in Nashville
July 9th 2025Packed with CE sessions, interactive learning, expert insights, and a vibrant expo floor, McKesson ideaShare 2025 aims to equip independent pharmacists with the tools and strategies to elevate patient care and drive pharmacy innovation.
Read More
Building a Sustainable Pharmacogenomics Program: A Pharmacist’s Perspective at Ochsner Health
July 7th 2025Serena Mitaly, PharmD, outlines how Ochsner Health is building a sustainable pharmacogenomics program by integrating clinical decision support tools into the EMR, educating providers, addressing reimbursement barriers, and expanding the role of PGx pharmacists in personalized medicine.
Read More
Sunvozertinib Approved by FDA as Oral Treatment of NSCLC With EGFR Exon 20 Insertion Mutations
July 7th 2025Sunvozertinib becomes the first and only targeted approval treatment for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
Read More